Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

High Hurdle For Novartis's New Oncology Division

Executive Summary

Novartis AG has nailed its oncology colors firmly to the mast by restructuring its pharmaceuticals division to separate out cancer from the rest of its pharma business. But the changes do not disguise the need to offset the loss of patent protection for its pioneering targeted anticancer blockbuster Gleevec (imatinib).

Advertisement

Related Content

Novartis Takes Aim At Systemic Mastocytosis With Midostaurin
Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early
Novartis Rejiggers Pharma To Favor Oncology

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel